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Objective: To determine the long-term objective and subjective outcomes of urethral sphincter injection
of onabotulinumtoxinA (OnaBoNT/A) in patients with acontractile bladder.
Materials and methods: We enrolled patients with acontractile bladder who received OnaBoNT/A injec-
tion in the urethral sphincter between May 2003 and April 2009. The objective outcome was assessed
based on the changes in postvoid residual urine (PVR) volume and the necessity of clean intermittent
catheterization (CIC). Abstinence from CIC with a decrease in PVR volume by more than 75% was deﬁned
as success. A decrease in PVR volume between 75% and 25% was deﬁned as improved. The treatment was
deﬁned as failed if the decrease in PVR volume is less than 25%. Subjective outcome was assessed by the
Clinical Global Impression of Improvement (CGI-I) questionnaire. CGI-I scores of 1 (very much improved)
and 2 (much improved) were considered clinically signiﬁcant improvement.
Results: The study included 26 patients (20 women and six men). Among these patients, nine (35%) had
successful treatment, 12 (46%) had some clinical improvement, and the treatment failed in ﬁve patients
(19%). In the 10 patients who needed CIC, one discontinued CIC and two reduced the frequency of CIC
after OnaBoNT/A injection. Nine patients received repeated injections. With a median follow-up of 32.8
months, only 33% patients reported clinically signiﬁcant improvement.
Conclusion: OnaBoNT/A injection into the urethral sphincter improved bladder emptying for patients
with acontractile bladder. However, only one-third of the patients obtained relevant subjective long-
term beneﬁt.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
OnabotulinumtoxinA (OnaBoNT/A) cleaves the 25-kDa synapto
somal-associated protein, which is a prerequisite for exocytosis of
neurotransmitters from nerve terminals, resulting in chemical
denervation.1 OnaBoNT/A reduces the release of norepinephrine,
which is the main neurotransmitter responsible for urethral
contraction, from the urethra.2 Injection of OnaBoNT/A into the ure-
thral sphincter seems to be a temporary sphincterotomy, which re-
laxes the urinary sphincter. This proceduremay reduce bladderoutlet
resistance and facilitate bladder emptying for patients with acon-
tractile bladder or detrusor underactivity.3
Previous studies collectively reported on the effects of urethral
OnaBoNT/A injection on urinary voiding symptoms due to various
causes, including acontractile bladder, detrusor underactivity, andtment of Surgery, Taipei Vet-
ai Road, Taipei 11217, Taiwan.
ciation. Published by Elsevier Taiwdetrusor sphincter dyssynergia (DSD).2e4 Nonetheless, the re-
ported number of patients with acontractile bladder is limited and
the true value of urethral OnaBoNT/A injection for patients without
any detrusor contractility is not yet well known. Thus, we reviewed
the treatment experiences of patients with acontractile bladder,
with speciﬁc focus on the long-term subjective outcome of treat-
ment in this patient group.
2. Materials and methods
We enrolled 20 women and six men with acontractile bladder
secondary to various causes who received urethral OnaBoNT/A
injections between May 2003 and April 2009 (Table 1). All patients
were conﬁrmed as having acontractile bladders based on the re-
sults of urodynamic studies. Acontractile detrusor is deﬁned as one
that does not demonstrate contractile activity during urodynamic
studies.5 All patients received self-paid 100 or 200 U of OnaBoNT/A
(BOTOX; Allergan, Inc., Irvine, CA, USA) injection in the area of the
urethral sphincter, under laryngeal mask anesthesia. In men,
transurethral OnaBoNT/A injection into the urethra sphincter wasan LLC. Open access under CC BY-NC-ND license.
Table 1
Causes of acontractile bladder.
Causes (N ¼ 26) N (%)
Idiopathic 7 (27)
Diabetes mellitus cystopathy 6 (23)
Meningomyelocele 5 (19)
Neurogenic bladder due to neurological disorder 3 (12)
Radical hysterectomy 3 (12)
Radiation for cervical cancer 1 (4)
Bladder BoN/T/A injection induced 1 (4)
Fig. 2. In female patients, OnaBoNT/A was injected into the urethral sphincter area
under transvaginal ultrasound guidance. Arrow: injection needle in the urethral wall.
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OnaBoNT/A injection was done under transvaginal ultrasound
guidance, using an ultrasound machine (BK Medical, Denmark)
with a 7.5-MHz transrectal ultrasound probe (Fig. 2). Approxi-
mately 100 U of OnaBoNT/Awas dissolved in 2 mL of normal saline.
About 0.5 mL of the solution was then injected at the 12, 3, 6, 9
o’clock positions of the sphincter. Sonographically measured
postvoid residual urine (PVR) volume and the frequency of clean
intermittent catheterization (CIC) were obtained 1 month after the
OnaBoNT/A injection.
Objective outcomes were assessed using the PVR volume and
the frequency of CIC. Decreases in PVR volume by more than 75%
were deﬁned as treatment success, decreases between 75% and 25%
were deﬁned as improvement, and decreases less than 25% were
deﬁned as treatment failure.
Long-term subjective outcomes were assessed using the Clinical
Global Impression of Improvement (CGI-I) score and the willing-
ness to receive repeated OnaBoNT/A injections.3 The CGI-I is a
seven-category scale and patients provided ratings of their overall
impressions on how they felt after the injection. CGI-I scores of 1
(very much improved) and 2 (much improved) were considered
clinically signiﬁcant improvements.
SPSS statistical analysis software (SPSS, Inc., Chicago, IL, USA)
was used for performing the statistical analyses. Descriptive sta-
tistics were applied to objective and subjective outcomes. Paired t
tests were used to compare the difference between preinjection
and postinjection variables. ManneWhitney test and Chi-square
test were used to evaluate the predictive factor for objective
outcome and subjective outcome. A p value <0.05 was considered
statistically signiﬁcant.
3. Results
Twenty-six patients, 20 women (age: 59.53  16.24 years;
range: 31.72e77.31) and six men (age: 33.42  15.64 years; range:Fig. 1. In male patients, OnaBoNT/Awas injected into the urethral sphincter area under
urethroscopic guidance.17.10e62.25) were enrolled in the study. Of them, 24 received 100 U
and two received 200 U of OnaBoNT/A injection.3.1. Objective outcome
Preinjection mean  standard deviation PVR volume was
302.5184.4 mL (range: 17e750), which was signiﬁcantly reduced
to 99.2  85.9 mL (range: 10e400) 1 month after the injection
(p < 0.001). Among these patients, nine (35%) were classiﬁed as
having treatment success, 12 (46%) were classiﬁed as having
improvement, and ﬁve (19%) were classiﬁed as having treatment
failure. There was no correlation between the cause of acontractile
bladder and objective outcome.
Among the 10 patients who performed CIC before the OnaBoNT/
A injection, one discontinued CIC, who was classiﬁed as having
improvement. In addition, the average value of a PVR reductionwas
66.8%, and two reduced the frequency of CIC after OnaBoNT/A
injection.3.2. Multiple injections
Nine patients received repeated OnaBoNT/A injections. Four
patients received two injections, three patients received three in-
jections, one patient received four injections, and one patient had
ﬁve injections. The median interval between any two injections
was 324.7  289.5 days (range: 62e1159).
These nine patientswere divided into two groups according to the
reason for the repeat injection. Group 1 included seven patients who
had symptomatic improvement after the ﬁrst injection and requested
a repeat injection following recurrent voiding difﬁculty. The dosage of
all repeated injectionswas100UofOnaBoNT/A. InGroup1, 85%of the
patients obtained objective improvement after the second injection
(Table 2). Group 2 consisted of two patients who complained of noTable 2
Therapeutic results of repeated injections in group 1 patients.
N ¼ 7 First injection Second injection
Outcome: success 3 (43%) 4 (57%)
Outcome: improved 3 (43%) 2 (28%)
Outcome: failed 1 (14%) 1 (14%)
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improved outcome and another obtained failed outcome. In order to
enforce the effect of medication, they received a repeated injection
with a higher dosage (200 U of OnaBoNT/A). Each of them received
two injections. Themean interval between the two injectionswas138
days (range: 121e155 days). Both of the patients obtained improved
objective outcomes after the second injectionwith 200UOnaBoNT/A.
3.3. Long-term subjective outcomes
Of the 26 total patients,18 (69%) responded to the questionnaire.
Following a median follow-up of 32.8 months (range: 4.0e75.3
months), 33% (N ¼ 6) patients reported clinically signiﬁcant
improvement (CGI-I scores of 1 or 2). None of them reported
“worse,” “much worse,” or “very much worse.”
Concerning patients’ willingness to receive repeated urethral
sphincter injections of OnaBoNT/A (Table 3), seven patients were
willing to receive repeated injections if they were free and four
patients were willing to receive repeated injections for a fee. In
contrast, 68% of patients did not agree to receive repeated in-
jections of OnaBoNT/A.
3.4. Predictive factors for objective outcomes
There was no single predictive factor for objective outcome. Age,
gender, preinjection PVR volume, and the cause of acontractile
bladder were not related to the objective outcomes. No predictive
factor for subjective outcome was found either. No statistical cor-
relation between the objective (PVR volume, or categorization as
“success,” “improved,” or “failed”) and subjective outcomes (CGI-I
score of 1 or 2) was found.
3.5. Complication with stress urinary incontinence
Four of the 26 (15%) patients complained of stress urinary in-
continence (SUI) after OnaBoNT/A injection. Radical hysterectomy
and diabetic cystopathy were thought to be the causes of acon-
tractile bladder. All of them were women who denied related
symptoms before, and received 100 U of OnaBoNT/A. The severity
of SUI was mild and self-limited. The median duration of SUI was
27.5 months (range: 12e49).
4. Discussion
Previous studies collectively reported on the effects that ure-
thral OnaBoNT/A injection had on urinary voiding symptoms due to
various causes, but the reported number of patients with impaired
bladder contractility is limited. Mokhless et al reported the effect of
urethral OnaBoNT/A injection on 10 children with non-neurogenic,
nonrelaxing sphincter dysfunction and showed a marked decrease
in PVR.6 Smith et al presented their single-institution experience in
patients who received OnaBoNT/A injections for a variety of lowerTable 3










Do I agree with the
repeat injection
at the same charge?
4 (22) 2 (11) 12 (67)
Do I agree with the
repeat injection
free of charge?
7 (39) 3 (17) 8 (44)urinary tract disorders, including 68 patients with neurogenic DSD
or bladder neck obstruction.2 The mean PVR volume decreased
signiﬁcantly from 250 to 88 mL. In addition, maximal voiding
pressures decreased from 81 to 52 cmH2O and the cystometric
capacity increased from 198 to 241 mL. Kuo reported the effect of
urethral OnaBoNT/A injections in 27 patients with idiopathic low
detrusor contractility and a signiﬁcant reduction in the PVR volume
and a signiﬁcant increase in the maximal ﬂow rate were noted.7 In
addition, 13 (48%) had recovery of detrusor contractility. Kuo re-
ported the satisfaction with urethral injection of OnaBoNT/A for
DSD in patients with spinal cord lesions (N ¼ 33), and overall
satisfactory results were perceived by 60.6% of the patients.8
Moreover, signiﬁcant improvements were noted in urodynamic
parameters, such as voiding detrusor pressure, maximum ﬂow rate,
and PVR volume. Liao and Kuo reported a high success rate of 97%
after urethral OnaBoNT/A injection in 32 patients with idiopathic
detrusor underactivity and a success rate of 76% in 33 patients with
detrusor areﬂexia.9
To our knowledge, this is the ﬁrst study focused on the effect of
urethral OnaBoNT/A injection on patients with acontractile bladder.
In our study, the rate of success, deﬁned as a decrease in PVR vol-
ume by more than 75%, was 35% (N ¼ 9) after urethral OnaBoNT/A
injection in patients with acontractile bladder. Following a median
follow-up of 32.8 months, 33% (N ¼ 6) patients still reported clin-
ically signiﬁcant improvement (CGI-I score of 1 or 2). Compared
with the short-term results of urethral OnaBoNT/A injection for
detrusor areﬂexia reported by Liao and Kuo, the success rate of the
our study was low (76% vs. 35%).9 In their study, a successful result
was deﬁned as patient satisfaction with the therapeutic outcome
plus one of the following: (1) patients with chronic urinary reten-
tion resumed spontaneous voiding, (2) a reduction in PVR volume
by more than 50%, and (3) patients voided adequately with a lower
detrusor pressure or lower abdominal pressure.9 Our deﬁnition of
success seems stricter than that of Liao and Kuo. Diverse deﬁnitions
of success and constitutions of patient populations could contribute
to the variable results.
In our study,15% of the patients complained of de novo SUI after
OnaBoNT/A injection. Smith et al. reported that 4% of patients with
neurogenic DSD or bladder neck obstruction noted either wors-
ening or new-onset of SUI after urethral OnaBoNT/A injection.2
Our study included patients with acontractile bladder, while
Smith et al included patients with DSD or bladder neck obstruc-
tion. The dosages of OnaBoNT/A used in our study were similar to
those used in the Smith et al’s study. The urethral pressure of
patients with DSD or bladder neck obstruction is properly higher
than in patients with acontractile bladder, which reduced the
possibility of SUI after urethral OnaBoNT/A injection. In our study,
there were three patients with acontractile bladder secondary to
radical hysterectomy, and two of them had the complication of
SUI, with fair outcome. The patients who received radical hyster-
ectomy were not contraindicated for urethral OnaBoNT/A injec-
tion, but should be informed about the complication before
injection.
In previous studies, the dosage of OnaBoNT/A for urethral in-
jection was reported as 50, 100, or 200 U.2,3 There was also no
signiﬁcant difference of dosage in patients with similar dysfunc-
tion, such as nonrelaxing urethral sphincter or detrusor underac-
tivity.3 The exact dose of OnaBoNT/A needed to achieve maximal
therapeutic effect is still undetermined.3 The relationship between
the dosage and complication was also unclear. Therefore, most of
our patients received 100 U of OnaBoNT/A, and only few patients
received 200 U.
Age, gender, preinjection PVR volume, and the cause of acon-
tractile bladder were not related to subjective or objective out-
comes of urethral OnaBoNT/A injection in patients with
C.-H. Chang et al. / Urological Science 24 (2013) 14e17 17acontractile bladder. Small patient number is one of the limitations
in our study, and larger patient scale might be help to ﬁnd whether
these relationships were established. Liao and Kuo reported the
most common causes of failed urethral OnaBoNT/A injection in
patients with voiding dysfunction, including inadequate abdominal
pressure to generate enough power to void, bladder neck
obstruction, and a high urethral sphincter tone.9 The cause of
bladder emptying failure determined the success rate of urethral
OnaBoNT/A injection. In addition, low abdominal muscle power
also played an important role. Patients with acontractile bladder
must void with abdominal straining even after urethral OnaBoNT/A
injection. Patients with a weak general condition could have
inadequate abdominal power, thus reducing the ability to void
adequately. However, the condition of abdominal staining while
voiding before and after urethral OnaBoNT/A injection was not
evaluated in our study.
Patients with bladder acontractility have few options. Without
the ability to generate a detrusor contraction, they often require an
indwelling catheter or CIC in order to empty their bladders. An
indwelling catheter is associated with signiﬁcant potential
morbidity that includes recurrent urinary tract infections, hema-
turia, bladder stone, urethral erosion, and bladder cancer.10e13 Pa-
tients require moderate hand function to manipulate the catheter
using the appropriate techniques.
In the present study, we sustained the therapeutic effects of
urethral OnaBoNT/A injections in patients with acontractile
bladder, which reduced PVR volume in a given period. Only 15% of
patients complained of SUI after OnaBoNT/A injection and the
severity of SUI was mild and self-limited. Therefore, urethral Ona-
BoNT/A injection is a viable treatment option in patients with
acontractile bladder.
It is reasonable to hypothesize that the greater the decrease in
PVR volume or the frequency of CIC, the greater the satisfaction
with OnaBoNT/A injection treatment. Nonetheless, it was rejected
by many of our patients. Similar results were also found in studies
of intra-articular injection of hyaluronic acid in ankle osteoarthritis.
Both of these two procedures/operations were symptom relief,
functional resumed, and required repeating for a period. The long-
term clinical beneﬁt was controversial and the cost-effective issue
needs to be addressed.14e16 It is also a limitation in practicing that
only 69% patients responded to the questionnaire. During the
outpatient follow-up, several ideas were retained and presumed to
explain why the subjective and objective outcomes were not
matched: nine of 10 patients continued CIC even the PVR was
reduced; patients have to pay for the medication, undergo the risk
of an operation, and have waiting times for re-admission of
approximately every 6 months. According to that result, we
assumed that some patients were unsatisﬁed with the treatment
because the outcome did not match their expectations.
Our inquiries into the subjective outcomes of OnaBoNT/A in-
jection showed that many patients hesitated to have repeated
treatment. They may not have been satisﬁed with the results or
the cost of the treatment. If we had monitored the patients much
longer, the number of the patients who wished to receive
repeated injections would be fewer than the number we inves-
tigated by questionnaire. Larger scale studies, longer follow-up,
and a questionnaire with greater detail are necessary to prove
the hypothesis.5. Conclusions
It appears that OnaBoNT/A injection into the urethral sphincter
improves bladder emptying temporarily in approximately 80% of
patients with acontractile bladders. Repeated injection is usually
necessary. About one-third of the patients obtained relevant sub-
jective long-term beneﬁt. The patients should be well informed
about possible complications and realistic outcomes before un-
dergoing OnaBoNT/A urethral injection for the treatment of acon-
tractile bladder.Conﬂicts of interest statement
The authors declare that they have no ﬁnancial or non-ﬁnancial
conﬂicts of interest related to the subject matter or materials dis-
cussed in the manuscript.Source of funding
None.References
1. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences
between type A preparations. Eur J Neurol 2006;13:2e10.
2. Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB. Single-insti-
tution experience in 110 patients with botulinum toxin A injection into bladder
or urethra. Urology 2005;65:37e41.
3. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary
tract dysfunction. J Urol 2003;170:1908e12.
4. Guy W. Clinical Global Impression (CGI). ECDEU Assessment Manual for
Psychopharmacology. 1976.
5. Abrams P, Cardozo L, Fall M, Grifﬁths D, Rosier P, Ulmsten U, et al. The
standardisation of terminology in lower urinary tract function: report from the
standardisation sub-committee of the International Continence Society. Urol-
ogy Jan 2003;61:37e49.
6. Mokhless I, Gaafar S, Fouda K, Shaﬁk M, Assem A. Botulinum A toxin urethral
sphincter injection in children with nonneurogenic neurogenic bladder. J Urol
2006;176:1767e70. discussion 1770.
7. Kuo HC. Recovery of detrusor function after urethral botulinum A toxin in-
jection in patients with idiopathic low detrusor contractility and voiding
dysfunction. Urology 2007;69:57e61. discussion 61e2.
8. Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor
sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn
2008;27:793e6.
9. Liao YM, Kuo HC. Causes of failed urethral botulinum toxin A treatment for
emptying failure. Urology 2007;70:763e6.
10. Broecker BH, Klein FA, Hackler RH. Cancer of the bladder in spinal cord injury
patients. J Urol 1981;125:196e7.
11. Hall MK, Hackler RH, Zampieri TA, Zampieri JB. Renal calculi in spinal cord-
injured patient: association with reﬂux, bladder stones, and Foley catheter
drainage. Urology 1989;34:126e8.
12. Hackler RH. Long-term suprapubic cystostomy drainage in spinal cord injury
patients. Br J Urol 1982;54:120e1.
13. Trautner BW, Darouiche RO. Role of bioﬁlm in catheter-associated urinary tract
infection. Am J Infect Control 2004;32:177e83.
14. DeGroot 3rd H, Uzunishvili S, Weir R, Al-omari A, Gomes B. Intra-articular
injection of hyaluronic acid is not superior to saline solution injection for ankle
arthritis: a randomized, double-blind, placebo-controlled study. J Bone Joint
Surg Am 2012;94:2e8.
15. Sun SF, Hsu CW, Sun HP, Chou YJ, Li HJ, Wang JL. The effect of three
weekly intra-articular injections of hyaluronate on pain, function, and
balance in patients with unilateral ankle arthritis. J Bone Joint Surg Am
2011;93:1720e6.
16. Salk RS, Chang TJ, D’Costa WF, Soomekh DJ, Grogan KA. Sodium hyaluronate in
the treatment of osteoarthritis of the ankle: a controlled, randomized, double-
blind pilot study. J Bone Joint Surg Am 2006;88:295e302.
